| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11439613 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
| US11819485 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(14 years from now) | |
Dhivy is owned by Avion Pharms.
Dhivy contains Carbidopa; Levodopa.
Dhivy has a total of 3 drug patents out of which 0 drug patents have expired.
Dhivy was authorised for market use on 12 November, 2021.
Dhivy is available in tablet;oral dosage forms.
Dhivy can be used as method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, treatment of parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
The generics of Dhivy are possible to be released after 28 March, 2039.
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Market Authorisation Date: 12 November, 2021
Treatment: Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg; Treatment of parkinson's disease, post-encephalitic ...
Dosage: TABLET;ORAL
DHIVY family patents
